WASHINGTON (AP) — Federal health officials have approved a new injectable drug to treat patients who have been exposed to the deadly toxin anthrax.
The Food and Drug Administration said it approved Anthim on Friday to treat inhalation anthrax, which can cause serious injury and death. The condition occurs when anthrax bacterial spores are inhaled.
Because anthrax is a potential bioterrorism weapon the U.S. government has been funding the development and production of therapies.
Anthim was developed by Elusys Therapeutics Inc. of Pine Brook, New Jersey, with support from the Biomedical Advanced Research and Development Authority. The government agency stockpiles vaccines, drugs and equipment for use during pandemics and other health emergencies.
Most Read Business Stories
- Boeing will hire hundreds of temporary employees at Moses Lake as it prepares for 737 MAX's return to service
- Where a recession might hurt the Puget Sound region worst | Jon Talton
- Amazon is harnessing the 'strange and remarkable' growth of independent sellers with new tools, investments
- FAA cautions airlines on maintenance of sensors that were key to 737 MAX crashes
- Amazon opens its largest campus building anywhere, in India